You are here

  • Home
  • Archive
  • Volume 9, Issue 10
  • Trough levels of ipilimumab in serum as a potential biomarker of clinical outcomes for patients with advanced melanoma after treatment with ipilimumab

Article metrics

Article menu
Immunotherapy biomarkers
Original research
Trough levels of ipilimumab in serum as a potential biomarker of clinical outcomes for patients with advanced melanoma after treatment with ipilimumab

 

Online download statistics by month:

Online download statistics by month: October 2021 to December 2022

AbstractFullPdf
Oct 2021718720192
Nov 202123023364
Dec 202116616655
Jan 2022858835
Feb 2022747734
Mar 2022979843
Apr 2022686826
May 2022656532
Jun 2022858737
Jul 20229910037
Aug 202210410554
Sep 2022969648
Oct 2022626325
Nov 2022797938
Dec 2022606028
Total20882105748